

and, as expected, there was an increase in the number of lymphocytes and an increase in the NK and LAK activity (Table 1). Although both patients stopped the treatment immediately after two courses, a reduction of the enlarged lymph nodes was observed confirming the effectiveness of this treatment in these diseases.

The introduction of IL-2 based therapy into clinical haematology has resulted in the attainment of reproducible responses in malignancies refractory to more conventional therapeutic approaches. Thus, these results suggest and confirm the potential role of IL-2 in the treatment of malignant lymphomas. For the future, it is more likely that new protocols should be considered in an attempt to prevent relapse and prolong remission in lymphoma patients by eliminating the minimal residual disease.

## Correction

**Chemoresistance in rat ovarian tumours** — In this article by W. J. Zeller and colleagues (Vol. 27, No. 1) p. 64, the legend to Fig. 4 was incorrect. It should have read "DNA interstrand cross-links (ISCL) after exposure to cisplatin. Hatched column (right) = 0.342/DDP and striped column (left) = 0.342".

1. Rosenberg SA, Grimm EA, McGrogan M, *et al.* Biological activity of recombinant human interleukin-2 produced in *Escherichia coli*. *Science* 1984, 233, 1412–1415.
2. Rosenberg SA, Lotze MT, Muul LM, *et al.* A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *N Engl J Med* 1987, 316, 889–897.
3. Paciucci PA, Holland JF, Glidewell O, *et al.* Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2 activated cells in patients with advanced cancer. *J Clin Oncol* 1989, 7, 869–878.
4. Lotzova E, Savary CA, Herberman RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. *J Immunol* 1987, 138, 2718–2727.
5. Fierro MT, Liao XS, Lusso P, *et al.* *In vitro* and *in vivo* susceptibility of human leukemic cells to lymphokine activated killer activity. *Leukemia* 1988, 2, 50–54.
6. Foa R, Meloni G, Tosti ??, *et al.* Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL-2): clinical and biological findings. *Bone Marrow Transplant* 1990, 6 (Suppl. 1), 98–102.
7. Allison MA, Jones SE, McGuffey P. Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia and selected solid tumors. *J Clin Oncol* 1989, 7, 75–80.
8. Lennert K. Classification of non-Hodgkin's lymphomas. In: Lennert K, *et al.* eds. *Malignant Lymphomas Other than Hodgkin's Disease: Histology, Cytology, Ultrastructure, Immunology*. Berlin, Springer 1978, 111–469.

**Acknowledgement**—This work was partially supported by Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan.